ӳ����ý

Anna Greka is a core institute member of the ӳ����ý of MIT and Harvard, where she also serves on the institute’s Executive Leadership Team. She is also a professor at Harvard Medical School and a physician in the Department of Medicine at Mass General Brigham. In her laboratory, Greka leads a program aimed at dissecting fundamental mechanisms of disrupted cellular homeostasis in genetically defined kidney, metabolic, and degenerative diseases, with a special focus on membrane proteins.

Leading multidisciplinary teams of scientists, Greka has uncovered opportunities to target convergent “nodal” biological pathways that underlie genetic diseases in unexpectedly diverse cell types and organs, for example in the kidney, the eye, and the brain. Many of these discoveries are making their way to clinical trials with promising results.

To fully harness the power of nodal biology, Greka founded the Ladders to Cures (L2C) Accelerator, an ambitious new initiative whose goal is to catalyze progress across the research ecosystem and accelerate advances toward treatments and cures for patients with genetic diseases.

Her work has been widely recognized with many awards including a Presidential Early Career Award for Scientists and Engineers (PECASE) and the Seldin-Smith Award for Pioneering Research from the American Society for Clinical Investigation (ASCI). Greka was selected as a U.S. National Academy of Medicine Emerging Leader Scholar and she was elected to serve as ASCI’s president. Internationally recognized as a thought leader in biomedicine, Greka was a featured speaker at TED2023. Aiming to advance the translation of scientific discoveries into treatments for patients, Greka serves as founder, board member, and scientific advisor to several biotechnology companies.

Greka holds an A.B. in biology from Harvard University, an M.D. from the Harvard-MIT program in Health Sciences and Technology (HST), and a Ph.D. in neurobiology from Harvard Medical School.

Photo by Martin Adolfsson